Oncogenic association of the Cbp/PAG adaptor protein with the Lyn tyrosine kinase in human B-NHL rafts

Blood

Volumn 111, Issue 4, 2008, Pages 2310-2320

  Tauzin, Sebastien ^a   Ding, Heidrun ^a   Khatib, Karim ^a   Ahmad, Ishtiaq ^b   Burdevet, Dimitri ^a   Van Echten Deckert, Gerhild ^c   Lindquist, Jonathan A ^d   Schraven, Burkhart ^d   Nasir ud Din, ^b   Borisch, Bettina ^a   Hoessli, Daniel C ^a,e  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^b Institute of Molecular Sciences and Bioinformatics Lahore   (Pakistan)

^c UNIVERSITY OF BONN   (Germany)

^d UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^e Centre Médical Universitaire   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; PROTEIN CBP; PROTEIN KINASE LYN; SIGNALOSOME; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; ENZYME ACTIVE SITE; NONHODGKIN LYMPHOMA; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

EID: 41349111083     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-05-090985     Document Type: Article

References (43)

1. Shaffer AL, Rosenwald A, Staudt LM. Lymphoid malignancies: the dark side of B-cell differentiation. Nat Rev Immunol. 2002;2:920-932.
2. Kuppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer. 2005;5:251-262.
3. Pham LV, Tamayo AT, Yoshimura LC, Lo P, Ford RJ. Inhibition of constitutive NF-κB activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol. 2003;171:88-95.
4. Semac I, Palomba C, Kulangara K, et al. Anti-CD20 therapeutic antibody rituximab modifies the functional organization of rafts/microdomains of B lymphoma cells. Cancer Res. 2003;63:534-540.
5. Ilangumaran S, Arni S, van Echten-Deckert G, Borisch B, Hoessli DC. Microdomain-dependent regulation of Lck and Fyn protein tyrosine kinases in T lymphocyte plasma membranes. Mol Biol Cell. 1999;10:891-905.
6. Hoessli DC, Ilangumaran S, Soltermann A, Robinson PJ, Borisch B, Nasir-ud-Din. Signaling through sphingolipid microdomains of the plasma membrane: the concept of signaling platform. Glycoconj J. 2000;17:1-7.
7. Wan W, Albom MS, Lu L, et al. Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells. Blood. 2006;107:1617-1623.
8. Brdicka T, Pavlistova D, Leo A, et al. Phosphoprotein associated with glycosphingolipid-enriched microdomains (PAG), a novel ubiquitously expressed transmembrane adaptor protein, binds the protein tyrosine kinase Csk and is involved in regulation of T cell activation. J Exp Med. 2000;191:1591-1604.
9. Kawabuchi M, Satomi Y, Takao T, et al. Transmembrane phosphoprotein Cbp regulates the activities of Src-family tyrosine kinases. Nature. 2000;404:999-1003.
10. Davidson D, Bakinowski M, Thomas ML, Horejsi V, Veillette A. phosphorylation-dependent regulation of T-cell activation by PAG/Cbp, a lipid raft-associated transmembrane adaptor. Mol Cell Biol. 2003;23:2017-2028.
11. Davidson D, Schraven B, Veillette A. PAG-associated FynT regulates calcium signaling and promotes anergy in T lymphocytes. Mol Cell Biol. 2007;27:1960-1973.
12. Yasuda K, Nagafuku M, Shima T, et al. Fyn is essential for tyrosine phosphorylation of Csk-binding protein/phosphoprotein associated with glycolipid-enriched microdomains in lipid rafts in resting cells. J Immunol. 2002;169:2813-2817.
13. Smida M, Posevitz-Fejfar A, Horejsi V, Schraven B, Lindquist JA. A novel negative regulatory function of PAG: blocking Ras activation. Blood. 2007;110:596-605.
14. Kitaura J, Kawakami Y, Maeda-Yamamoto M, Horejsi V, Kawakami T. Dysregulation of Src family kinases in mast cells from epilepsy-resistant ASK versus epilepsy-prone EL mice. J Immunol. 2007;178:455-462.
15. Bergman M, Mustelin T, Oetken C, et al. The human p50(csk) tyrosine kinase phosphorylates p56(lck) at Tyr-505 and down regulates its catalytic activity. EMBO J. 1992;11:2919-2924.
16. Cary LA, Cooper JA. Molecular switches in lipid rafts. Nature. 2000;404:945-947.
17. Chong YP, Muhlern TD, Cheng HC. C-terminal Src kinase (CSK) and CSK-homologous kinase (CHK)-endogenous negative regulators of Src-family kinases. Growth Factors. 2005;23:233-244.
18. Baumgartner M, Angelisova P, Setterblad N, et al. Constitutive exclusion of Csk from Hck-positive membrane microdomains permits Src kinase-dependent proliferation of Theileria-transformed B lymphocytes. Blood. 2003;101:1874-1881.
19. Horejsi V, Zhang W, Schraven B. Transmembrane adaptor proteins: organizers of immunoreceptor signalling. Nature Rev Immunol. 2004;4:603-616.
20. Anderson RW, Jacobson K. A role for lipid shells in targeting proteins to caveolae, rafts and other lipid domains. Science. 2002;296:1821-1825.
21. Wiznerowicz M, Trono D. Conditional suppression of cellular genes: lentivirus vecto-mediated drug-inducible RNA interference. J Virol. 2003;77:8957-8961.
22. Rucci N, Recchia I, Angelucci A, et al. Inhibition of protein kinase c-Src reduces the incidence of breast cancer metastases and increases survival in mice: implications for therapy. J Pharmacol Exp Ther. 2006;318:161-172.
23. Chivian D, Kim D, Malmstrom L, et al. Automated prediction of CASP-5 structures using the Robetta server. Proteins. 2003;53:524-533.
24. Koradi R, Billeter M, Wuthrich K. A program for display and analysis of macromolecular structures. J Mol Graphics. 1996;14:51-55.
25. Comeau S, Gatchell D, Vajda S, Camacho C. ClusPro: an automated docking and discrimination method for the prediction of protein complexes. Bioinformatics. 2004;20:45-50.
26. Sobolev V, Eyal E, Gerzon S, et al. SPACE: a suite of tools for protein structure prediction and analysis based on complementarity and environment. Nucleic Acids Res. 2005;33:W39-W43.
27. Ohtake H, Ichikawa N, Okada M, Yamashita T. Cutting edge: transmembrane phosphoprotein Csk-binding protein/phosphoprotein associated with glycosphingolipid-enriched microdomains as a negative feedback regulator of mast cell signaling rhrough the Fcε RI. J Immunol. 2002;168:2087-2090.
28. Dráberová LA, Amoui M, Draber P. Thy-1-mediated activation of rat mast cells: the role of Thy-1 membrane microdomains. Immunology. 1996;87:141-148.
29. Mangeney M, Lingwood CA, Taga S, Caillou B, Tursz T, Wiels J. Apoptosis induced in Burkitt's lymphoma cells via Gb3/CD77, a glycolipid antigen. Cancer Res. 1993;53:5314-5319.
30. Chiarle R, Simkons WJ, Cai H, et al. Stat3 is required for ALK-mediated lymphomygenesis and provides a possible therapeutic target. Nat Med. 2005;11:623-629.
31. Holtick U, Vockerodt M, Pinkert D, et al. STAT3 is essential for Hodgkin lymphoma cell proliferation and is a target of tyrphostin AG17 which confers sensitization for apoptosis. Leukemia. 2005;19:936-944.
32. Donella-Deana A, Cesaro L, Ruzzene M, Brunati AM, Marin O, Pinna LA. Spontaneous autophosphorylation of Lyn tyrosine kinase at both its activation segment and C-terminal tail confers altered substrate specificity. Biochemistry. 1998;37:1438-1446.
33. Contri A, Brunati AM, Trentin L, et al. Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. J Clin Invest. 2005;115:369-378.
34. Chakraborty A, Dyer KF, Cascio M, Mietzner TA, Tweardy DJ. Identification of a novel Stat3 recruitment and activation motif within the granulocyte colony-stimulating factor receptor. Blood. 1999;93:15-24.
35. Sharma SV, Gajowniczek P, Way IP, et al. A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell. 2006;10:425-435.
36. Sharma SV, Fischbach MA, Haber DA, Settleman J. "Oncogenic shock": explaining oncogene addiction through differential signal attenuation. Clin Cancer Res. 2006;12:4392-4395.
37. Prakash O, Swamy OR, Peng X, et al. Activation of Src kinase Lyn by the Kaposi sarcoma-associated herpesvirus K1 protein: implications for lymphomagenesis. Blood. 2005;105:3987-3994.
38. Dai Y, Rahmani M, Corey SJ, Dent P, Grant S. A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J Biol Chem. 2004;279:34227-34239.
39. Hu Y, Liu Y, Pelletier S, et al. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet. 2004;36:453-461.
40. Sprangers M, Feldhahn N, Herzog S, et al. The SRC family kinase LYN redirects B cell receptor signaling in human SLP65-deficient B cell lymphoma cells. Oncogene. 2006;25:5056-5062.
41. Dobenecker M-W, Schmedt C, Okada M, Tarakhovsky A. The ubiquitously expressed Csk adaptor protein Cbp is dispensable for embryogenesis and T-cell development and function. Mol Cell Biol. 2005;25:10533-10542.
42. Xu S, Huo J, Tan JEL, Lam KP. Cbp deficiency alters Csk localization in lipid rafts but does not affect T-cell development. Mol Cell Biol. 2005;25:8486-8495.
43. Sun Y, Orrenius S, Pervaiz S, Fadeel B. Plasma membrane sequestration of apoptotic protease-activating factor-1 in human B lymphoma cells: a novel mechanism of chemoresistance. Blood. 2005;105:4070-4077.